Reported Earlier, GSK's Interim Analysis Of The DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin Combination Shows 50% Reduction In Disease Progression Risk In Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
GSK's DREAMM-8 Phase III trial shows a 50% reduction in disease progression risk for multiple myeloma with belantamab mafodotin combination. The trial demonstrated significant improvement in progression-free survival (PFS) compared to the bortezomib combination.
June 03, 2024 | 6:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GSK's DREAMM-8 Phase III trial shows a 50% reduction in disease progression risk for multiple myeloma with belantamab mafodotin combination. The trial demonstrated significant improvement in progression-free survival (PFS) compared to the bortezomib combination.
The positive results from the DREAMM-8 Phase III trial indicate a significant advancement in treatment for multiple myeloma, which is likely to boost investor confidence and positively impact GSK's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100